Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer.
Colorectal cancer is the third most common form of cancer. Current treatments are all associated with a high risk of complications and a low success rate. Recently, synbiotics have been proposed as a new preventive and therapeutic option. There is no direct experimental evidence for cancer suppression in humans as a result of the consumption of pro-, pre- or synbiotics. However, there is a wealth of evidence emerging from laboratory studies. The mechanisms by which pro-, pre- and synbiotics may inhibit colon cancer are now beginning to be understood and will be addressed in the present review.
Fotiadis
Constantine-Iosif
CI
3rd Surgical Clinic of the University hospital 'ATTIKON', Rimini 1, 12462, Haidari, Greece. costfot@yahoo.gr
Stoidis
Christos-Nikolaou
CN
Spyropoulos
Basileios-Georgiou
BG
Zografos
Eleftherios-Dimitriou
ED
D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*; D019587:Dietary Supplements; D006801:Humans; D019936:Probiotics / Q000627:therapeutic use*; D016896:Treatment Outcome
D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents